Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ADK | P55263 | 1/20 | 0.32 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23959988 | 0.91 | TMPRSS2 (0.66) | TMPRSS2 | |
| SCHEMBL26004234 | 0.89 | TMPRSS2 (0.62) | TMPRSS2MAP4K4ADORA3ADORA1 | |
| SCHEMBL25216402 | 0.87 | TMPRSS2 (0.62) | TMPRSS2ADORA3ADORA1 | |
| SCHEMBL12393420 | 0.86 | TMPRSS2 (0.58) | TMPRSS2 | |
| SCHEMBL30960132 | 0.86 | TMPRSS2 (0.71) | TMPRSS2 | |
| SCHEMBL30363087 | 0.85 | TMPRSS2 (0.59) | TMPRSS2 | |
| SCHEMBL24789761 | 0.85 | TMPRSS2 (0.67) | TMPRSS2ADORA1 | |
| SCHEMBL30973747 | 0.84 | TMPRSS2 (0.66) | TMPRSS2 | |
| SCHEMBL30973738 | 0.84 | TMPRSS2 (0.66) | TMPRSS2 | |
| SCHEMBL30973741 | 0.84 | TMPRSS2 (0.66) | TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241225-A1 | ANTI-VIRAL COMPOUNDS AND METHODS OF USE | METRO INTERNATIONAL BIOTECH, LLC | 2023-08-03 | — | — | US | disclosed |
| US-20210388019-A1 | ANTI-VIRAL COMPOUNDS AND METHODS OF USE | METRO INTERNATIONAL BIOTECH, LLC | 2021-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210388019-A1 | ANTI-VIRAL COMPOUNDS AND METHODS OF USE | SARS1, MAVS, NME4 | TMPRSS2 42/4885MAP4K4 1770/4885ADORA3 839/4885 |
| US-20230241225-A1 | ANTI-VIRAL COMPOUNDS AND METHODS OF USE | SARS1, MAVS, NME4 | TMPRSS2 42/4885MAP4K4 1770/4885ADORA3 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.